Carl Zeiss Meditec AG

XTRA:AFX Stock Report

Market Cap: €4.8b

Carl Zeiss Meditec Future Growth

Future criteria checks 2/6

Carl Zeiss Meditec is forecast to grow earnings and revenue by 19.4% and 6.6% per annum respectively. EPS is expected to grow by 18.4% per annum. Return on equity is forecast to be 11.3% in 3 years.

Key information

19.4%

Earnings growth rate

18.4%

EPS growth rate

Medical Equipment earnings growth14.4%
Revenue growth rate6.6%
Future return on equity11.3%
Analyst coverage

Good

Last updated18 Feb 2025

Recent future growth updates

Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 11
Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively

Feb 10
Carl Zeiss Meditec (ETR:AFX) Might Be Having Difficulty Using Its Capital Effectively

More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%

Jan 10
More Unpleasant Surprises Could Be In Store For Carl Zeiss Meditec AG's (ETR:AFX) Shares After Tumbling 26%

Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?

Dec 28
Is Carl Zeiss Meditec AG (ETR:AFX) Potentially Undervalued?

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Dec 04
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk

Nov 19
Carl Zeiss Meditec AG's (ETR:AFX) Share Price Could Signal Some Risk

Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital

Sep 19
Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital

Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Sep 06
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?

Aug 23
Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?

At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?

Aug 09
At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?

Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Jul 11
Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled

Jun 10
Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled

Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing

May 26
Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing

Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 11
Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

May 09
Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)

Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?

Mar 24
Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?

Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Mar 11
Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

XTRA:AFX - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20272,525250227N/A12
9/30/20262,338201205N/A14
9/30/20252,184152135N/A15
12/31/20242,082157N/AN/AN/A
9/30/20242,06617995247N/A
6/30/20242,066203N/AN/AN/A
3/31/20242,062261122263N/A
12/31/20232,094277N/AN/AN/A
9/30/20232,089290137251N/A
6/30/20232,080308N/AN/AN/A
3/31/20232,02227863162N/A
12/31/20221,963307N/AN/AN/A
9/30/20221,903294106188N/A
6/30/20221,781245N/AN/AN/A
3/31/20221,735264207285N/A
12/31/20211,688228N/AN/AN/A
9/30/20211,647236297363N/A
6/30/20211,566235N/AN/AN/A
3/31/20211,388159240290N/A
12/31/20201,335130N/AN/AN/A
9/30/20201,335122134179N/A
6/30/20201,400120N/AN/AN/A
3/31/20201,507166132171N/A
12/31/20191,505170N/AN/AN/A
9/30/20191,459160173220N/A
6/30/20191,382153N/AN/AN/A
3/31/20191,334129195242N/A
12/31/20181,310127N/AN/AN/A
9/30/20181,281126N/A187N/A
6/30/20181,251124N/AN/AN/A
3/31/20181,216129N/A56N/A
12/31/20171,205132N/AN/AN/A
9/30/20171,190134N/A38N/A
6/30/20171,154123N/AN/AN/A
3/31/20171,135112N/A85N/A
12/31/20161,106113N/AN/AN/A
9/30/20161,08898N/A112N/A
6/30/20161,09078N/A132N/A
3/31/20161,08380N/A96N/A
12/31/20151,06261N/A73N/A
9/30/20151,04062N/A57N/A
6/30/201598470N/A34N/A
3/31/201594666N/A44N/A
12/31/201493873N/A60N/A
9/30/201490975N/A63N/A
6/30/201493183N/A74N/A
3/31/201492489N/A69N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFX's forecast earnings growth (19.4% per year) is above the savings rate (1.1%).

Earnings vs Market: AFX's earnings (19.4% per year) are forecast to grow slower than the German market (19.8% per year).

High Growth Earnings: AFX's earnings are forecast to grow, but not significantly.

Revenue vs Market: AFX's revenue (6.6% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: AFX's revenue (6.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AFX's Return on Equity is forecast to be low in 3 years time (11.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 15:51
End of Day Share Price 2025/02/20 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Carl Zeiss Meditec AG is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Scott BardoBerenberg
Julien OuaddourBofA Global Research